Oncology
FDA/CDC
FDA approves pembrolizumab for advanced SCLC
The approval was based on an overall response rate of 19% in two nonrandomized trials.
Conference Coverage
EULAR issues guidelines on managing rheumatic complications of cancer immunotherapies
The new guidelines are tailored for rheumatologists, and address diagnosis and treatment.
FDA/CDC
FDA approves trastuzumab-anns for HER2-positive breast, gastric cancer
This is the fifth FDA approval of a trastuzumab biosimilar.
Conference Coverage
Pregnancy deemed safe in BRCA-mutated breast cancer survivors
Pregnancy did not affect disease-free or overall survival, and complications were similar to the general population.
FDA/CDC
The costs of surviving cancer
Annual out-of-pocket spending is 60% higher for survivors, the CDC reported.
Conference Coverage
Nephrectomy may benefit select renal cancer patients based on risk factors
CHICAGO – CARMENA update confirms cytoreductive nephrectomy should not be standard of care for most cases of metastatic renal cell carcinoma.
Clinical Review
Chronic Myeloid Leukemia: Selecting First-line TKI Therapy
Conference Coverage
Cleveland Clinic targets time to treat in cancer
CHICAGO – The Taussig Cancer Institute at the Cleveland Clinic reduced the time to treat for newly diagnosed cancer patients by 33%. Taussig’s...
Conference Coverage
TITAN trial yields big survival benefits in mCSPC
CHICAGO – Adding apalutamide to androgen deprivation therapy significantly improved overall survival of castration-...
Conference Coverage
Cultural competence behaviors linked to higher patient satisfaction scores
SAN DIEGO – The mean cultural behavior score was a 4.1 out of a possible 7 points.